孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘疗效观察  

Effect of montelukast plus ambroxol on cough variant asthma in children

作　　者：谭鑫[1] 

机构地区：[1]郑州市妇幼保健院新生儿科,450000

出　　处：《中华实用诊断与治疗杂志》2016年第5期515-516,共2页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的探讨孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘的效果和安全性。方法咳嗽变异性哮喘患儿76例，随机分为观察组39例和对照组37例。对照组给予孟鲁司特3-5mg／次，1次／d，睡前口服；观察组在对照组治疗基础上给予氨溴特罗口服液5-15mL／次，1次／d，口服；2组疗程均为14d。记录2组咳嗽及肺部哕音消失时间；比较2组治疗前、后第1秒用力呼气容积（forced expiratory volume in one second，FEV1），FEV1／用力肺活量（forced vital capacity，FVC）（FEV1／FVC）、最大呼气流量（peak expiratory flow，PEF）。结果观察组咳嗽消失时间[（6．12±1．28）d]、肺部哕音消失时间[（7．18±1．75）d]均较对照组[（9．85±2．03）、（11．03±2．17）d]缩短（P〈0．05）；观察组治疗后FEV1[（82．42±8．94）％]、FEV1／FVC[（81．52±7．89）％]、PEF[（90．79±8．33）L／s]均较治疗前[（76．13±10．64）％、（75．21±10．23）％、（84．91±12．54）L／s]增高（P〈0．05）；对照组治疗后FEV1[（78．05±9．43）％]、FEV1／FVC[（77．86±8．45）％]、PEF[（86．33±9．19）L／s]与治疗前[（75．89±10．49）％、（74．93±10．07）％、（84．68±12．47）L／s]比较差异无统计学意义（P〉0.05）；观察组治疗后各指标水平均高于对照组（P〈0.05）。结论孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘可明显改善患儿肺功能，缩短咳嗽及肺部哕音消失时间。Objective To explore the effect and safety of montelukast plus ambroxol in the treatment of cough variant asthma in children. Methods Seventy-six children with cough variant asthma were randomly divided into observation group （n=39） and control group （n=37）. Control group was orally given montelukast, 3 to 5 mg per time, once a day before sleep. Observation group was given ambroxo] oral solution besides the treatment in control group, 5 to 15 mL per time, once a day. The treatment course was 14 days. The disappearance time of cough and pulmonary rales were recorded. And the forced expiratory volume in one second （FEV1）, FEV1/ forced vital capacity （FVC） and peak expiratory flow （PEF） were detected and compared between two groups. Results The disappearance time of cough and pulmonary rales were significantly shorter in observation group （（6.12 ± 1.28）, （7.18 ±1.75） d） that those in control group （（9.85±2.03）, （11.03±2. 17） d） （P〈0.05）. FEV1, FEV1/FVC and PEF （（82. 42±8.94）%, （81. 52±7.89） %, （90.79±8.33） L/s） were significantly higher after treatment that those before treatment in observation group （（76.13±10.64）%, （75. 21±10.23）%, （84. 91±12.54）L/s） （P〈0.05）. There were no significant differences in the scores of FEV1 （（78.05±9.43） %, （75.80±10.49） %）, FEV1/FVC （（77.86±8.45） %, （74. 93±10.07） %） and PEF （（86.33 ±9.19）, （84.68 ±12.47） L/s） after treatment in comparison with those before treatment in control group （P〉 0.05）. The above indicators in observation group were significantly higher than those in control group after treatment （P〈0.05）. Conclusion Montelukast plus ambroxol can effectively improve lung function and shorten the disappearance time of cough and pulmonary rales in children with cough variant asthma.

关 键 词：咳嗽变异性哮喘 儿童 氨溴特罗 孟鲁司特 

分 类 号：R725.6[医药卫生—儿科]